A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

For more information regarding Bristol-Myers Squibb Clinical Trial participation, pleasevisit www.BMSStudyConnect.com Inclusion Criteria:

• Histological confirmation of RCC with a clear-cell component, including participantswho may also have sarcomatoid features
• Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCCStage IV) RCC
• No prior systemic therapy for RCC with the following exception: i) One prior adjuvant or neoadjuvant therapy for completely resectable RCC if suchtherapy did not include an agent that targets VEGF or VEGF receptors and if recurrenceoccurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy

Exclusion Criteria:

• Any active CNS metastases
• Any active, known or suspected autoimmune disease
• Any condition requiring systemic treatment with either corticosteroids (> 10 mg dailyprednisone equivalent) or other immunosuppressive medications within 14 days ofrandomization
• Participants who have received a live/attenuated vaccine within 30 days of firsttreatment Other protocol defined inclusion/exclusion criteria could apply